A Randomized Trial of Sirolimus-Based Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation in Relapsed Acute Lymphoblastic Leukemia.

Trial Profile

A Randomized Trial of Sirolimus-Based Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation in Relapsed Acute Lymphoblastic Leukemia.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs Sirolimus (Primary) ; Cyclophosphamide; Methotrexate; Tacrolimus; Thiotepa
  • Indications Acute lymphoblastic leukaemia; Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Dec 2016 Status changed from discontinued to active, no longer recruiting.
    • 04 Dec 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 03 Aug 2012 Planned end date changed from 1 Feb 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top